KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Liabilities (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Total Liabilities data on record, last reported at $122.1 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 24.01% year-over-year to $122.1 million; the TTM value through Dec 2025 reached $122.1 million, down 24.01%, while the annual FY2025 figure was $122.1 million, 24.01% down from the prior year.
  • Total Liabilities reached $122.1 million in Q4 2025 per RIGL's latest filing, down from $124.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $160.7 million in Q4 2024 and bottomed at $122.1 million in Q4 2025.
  • Average Total Liabilities over 5 years is $142.4 million, with a median of $143.7 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 112.28% in 2021, then decreased 24.01% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $137.0 million in 2021, then grew by 7.99% to $147.9 million in 2022, then decreased by 1.37% to $145.9 million in 2023, then increased by 10.16% to $160.7 million in 2024, then decreased by 24.01% to $122.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $122.1 million in Q4 2025, $124.9 million in Q3 2025, and $124.8 million in Q2 2025.